<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2019//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_190101.dtd">
<PubmedArticleSet>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated">
      <PMID Version="1">35292437</PMID>
      <DateRevised>
        <Year>2022</Year>
        <Month>05</Month>
        <Day>11</Day>
      </DateRevised>
      <Article PubModel="Print-Electronic">
        <Journal>
          <ISSN IssnType="Electronic">1533-3450</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>33</Volume>
            <Issue>5</Issue>
            <PubDate>
              <Year>2022</Year>
              <Month>May</Month>
            </PubDate>
          </JournalIssue>
          <Title>Journal of the American Society of Nephrology : JASN</Title>
          <ISOAbbreviation>J Am Soc Nephrol</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Targeting Cathepsin C in PR3-ANCA Vasculitis.</ArticleTitle>
        <Pagination>
          <StartPage>936</StartPage>
          <EndPage>947</EndPage>
          <MedlinePgn>936-947</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="doi" ValidYN="Y">10.1681/ASN.2021081112</ELocationID>
        <Abstract>
          <AbstractText Label="BACKGROUND">The ANCA autoantigens proteinase 3 (PR3) and myeloperoxidase (MPO) are exclusively expressed by neutrophils and monocytes. ANCA-mediated activation of these cells is the key driver of the vascular injury process in ANCA-associated vasculitis (AAV), and neutrophil serine proteases (NSPs) are disease mediators. Cathepsin C (CatC) from zymogens activates the proteolytic function of NSPs, including PR3. Lack of NSP zymogen activation results in neutrophils with strongly reduced NSP proteins.</AbstractText>
          <AbstractText Label="METHODS">To explore AAV-relevant consequences of blocking NSP zymogen activation by CatC, we used myeloid cells from patients with Papillon-Lefèvre syndrome, a genetic deficiency of CatC, to assess NSPs and NSP-mediated endothelial cell injury. We also examined pharmacologic CatC inhibition in neutrophil-differentiated human hematopoietic stem cells, primary human umbilical vein cells, and primary glomerular microvascular endothelial cells.</AbstractText>
          <AbstractText Label="RESULTS">Patients with Papillon-Lefèvre syndrome showed strongly reduced NSPs in neutrophils and monocytes. Neutrophils from these patients produced a negative PR3-ANCA test, presented less PR3 on the surface of viable and apoptotic cells, and caused significantly less damage in human umbilical vein cells. These findings were recapitulated in human stem cells, in which a highly specific CatC inhibitor, but not prednisolone, reduced NSPs without affecting neutrophil differentiation, reduced membrane PR3, and diminished neutrophil activation upon PR3-ANCA but not MPO-ANCA stimulation. Compared with healthy controls, neutrophils from patients with Papillon-Lefèvre syndrome transferred less proteolytically active NSPs to glomerular microvascular endothelial cells, the cell type targeted in ANCA-induced necrotizing crescentic glomerulonephritis. Finally, both genetic CatC deficiency and pharmacologic inhibition, but not prednisolone, reduced neutrophil-induced glomerular microvascular endothelial cell damage.</AbstractText>
          <AbstractText Label="CONCLUSIONS">These findings may offer encouragement for clinical studies of adjunctive CatC inhibitor in patients with PR3-AAV.</AbstractText>
          <CopyrightInformation>Copyright © 2022 by the American Society of Nephrology.</CopyrightInformation>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Jerke</LastName>
            <ForeName>Uwe</ForeName>
            <Initials>U</Initials>
            <AffiliationInfo>
              <Affiliation>Experimental and Clinical Research Center, Max Delbrueck Center for Molecular Medicine and Charité-Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin, Humboldt-Universität zu Berlin, Berlin Institute of Health, Berlin, Germany.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Eulenberg-Gustavus</LastName>
            <ForeName>Claudia</ForeName>
            <Initials>C</Initials>
            <Identifier Source="ORCID">0000-0002-2425-2275</Identifier>
            <AffiliationInfo>
              <Affiliation>Experimental and Clinical Research Center, Max Delbrueck Center for Molecular Medicine and Charité-Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin, Humboldt-Universität zu Berlin, Berlin Institute of Health, Berlin, Germany.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Rousselle</LastName>
            <ForeName>Anthony</ForeName>
            <Initials>A</Initials>
            <AffiliationInfo>
              <Affiliation>Experimental and Clinical Research Center, Max Delbrueck Center for Molecular Medicine and Charité-Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin, Humboldt-Universität zu Berlin, Berlin Institute of Health, Berlin, Germany.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Nicklin</LastName>
            <ForeName>Paul</ForeName>
            <Initials>P</Initials>
            <AffiliationInfo>
              <Affiliation>Boehringer Ingelheim Pharma GmbH &amp; Co., KG, Biberach, Germany.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Kreideweiss</LastName>
            <ForeName>Stefan</ForeName>
            <Initials>S</Initials>
            <AffiliationInfo>
              <Affiliation>Boehringer Ingelheim Pharma GmbH &amp; Co., KG, Biberach, Germany.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Grundl</LastName>
            <ForeName>Marc A</ForeName>
            <Initials>MA</Initials>
            <AffiliationInfo>
              <Affiliation>Boehringer Ingelheim Pharma GmbH &amp; Co., KG, Biberach, Germany.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Eickholz</LastName>
            <ForeName>Peter</ForeName>
            <Initials>P</Initials>
            <AffiliationInfo>
              <Affiliation>Peridontology, Johann Wolfgang Goethe-University Frankfurt, Frankfurt/Main, Germany.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Nickles</LastName>
            <ForeName>Katrin</ForeName>
            <Initials>K</Initials>
            <AffiliationInfo>
              <Affiliation>Peridontology, Johann Wolfgang Goethe-University Frankfurt, Frankfurt/Main, Germany.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Schreiber</LastName>
            <ForeName>Adrian</ForeName>
            <Initials>A</Initials>
            <AffiliationInfo>
              <Affiliation>Experimental and Clinical Research Center, Max Delbrueck Center for Molecular Medicine and Charité-Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin, Humboldt-Universität zu Berlin, Berlin Institute of Health, Berlin, Germany.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Nephrology and Medical Intensive Care Medicine, Charité-Universitätsmedizin Berlin, Berlin, Germany.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Korkmaz</LastName>
            <ForeName>Brice</ForeName>
            <Initials>B</Initials>
            <AffiliationInfo>
              <Affiliation>INSERM U-1100 Université de Tours, Tours, France.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Kettritz</LastName>
            <ForeName>Ralph</ForeName>
            <Initials>R</Initials>
            <Identifier Source="ORCID">0000-0001-5821-6718</Identifier>
            <AffiliationInfo>
              <Affiliation>Experimental and Clinical Research Center, Max Delbrueck Center for Molecular Medicine and Charité-Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin, Humboldt-Universität zu Berlin, Berlin Institute of Health, Berlin, Germany ralph.kettritz@charite.de.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Nephrology and Medical Intensive Care Medicine, Charité-Universitätsmedizin Berlin, Berlin, Germany.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
          <PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
        </PublicationTypeList>
        <ArticleDate DateType="Electronic">
          <Year>2022</Year>
          <Month>03</Month>
          <Day>15</Day>
        </ArticleDate>
      </Article>
      <MedlineJournalInfo>
        <Country>United States</Country>
        <MedlineTA>J Am Soc Nephrol</MedlineTA>
        <NlmUniqueID>9013836</NlmUniqueID>
        <ISSNLinking>1046-6673</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D019268">Antibodies, Antineutrophil Cytoplasmic</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D004792">Enzyme Precursors</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>EC 1.11.1.7</RegistryNumber>
          <NameOfSubstance UI="D009195">Peroxidase</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>EC 3.4.14.1</RegistryNumber>
          <NameOfSubstance UI="D020789">Cathepsin C</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>EC 3.4.21.76</RegistryNumber>
          <NameOfSubstance UI="D053146">Myeloblastin</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <CommentsCorrectionsList>
        <CommentsCorrections RefType="CommentIn">
          <RefSource>J Am Soc Nephrol. 2022 May;33(5):875-878</RefSource>
          <PMID Version="1">35396261</PMID>
        </CommentsCorrections>
      </CommentsCorrectionsList>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D056648" MajorTopicYN="Y">Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D019268" MajorTopicYN="N">Antibodies, Antineutrophil Cytoplasmic</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D020789" MajorTopicYN="N">Cathepsin C</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D042783" MajorTopicYN="N">Endothelial Cells</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D004792" MajorTopicYN="N">Enzyme Precursors</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D053146" MajorTopicYN="N">Myeloblastin</DescriptorName>
          <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D009504" MajorTopicYN="N">Neutrophils</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D010214" MajorTopicYN="Y">Papillon-Lefevre Disease</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D009195" MajorTopicYN="N">Peroxidase</DescriptorName>
        </MeshHeading>
      </MeshHeadingList>
      <KeywordList Owner="NOTNLM">
        <Keyword MajorTopicYN="Y">ANCA</Keyword>
        <Keyword MajorTopicYN="Y">cathepsin C</Keyword>
        <Keyword MajorTopicYN="Y">endothelial cells</Keyword>
        <Keyword MajorTopicYN="Y">immunology</Keyword>
        <Keyword MajorTopicYN="Y">vasculitis</Keyword>
      </KeywordList>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="received">
          <Year>2021</Year>
          <Month>8</Month>
          <Day>20</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="accepted">
          <Year>2022</Year>
          <Month>2</Month>
          <Day>2</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2022</Year>
          <Month>3</Month>
          <Day>17</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2022</Year>
          <Month>5</Month>
          <Day>4</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2022</Year>
          <Month>3</Month>
          <Day>16</Day>
          <Hour>5</Hour>
          <Minute>55</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>ppublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">35292437</ArticleId>
        <ArticleId IdType="doi">10.1681/ASN.2021081112</ArticleId>
        <ArticleId IdType="pii">ASN.2021081112</ArticleId>
      </ArticleIdList>
    </PubmedData>
  </PubmedArticle>
</PubmedArticleSet>
